28400582|t|Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis
28400582|a|Serum anti-mitochondrial antibody type 2 (AMA-M2) is considered as a pivotal biomarker for the diagnosis of primary biliary cholangitis (PBC). However, serological tests have many limitations, including inconvenience, invasiveness, and infection risks. Thus, a less invasive approach to detect AMA-M2 titer is desirable. We examined salivary AMA-M2 of potential PBC patients and found that AMA-M2 could be detected only in saliva of serum AMA-M2-positive PBC patients, but not in saliva of serum AMA-M2-negative PBC patients, oral lichen planus patients (OLP) patients, or healthy controls. Furthermore, the concentration of salivary AMA-M2 was positively correlated with the amount of serum AMA-M2 in patients. The salivary inflammatory cytokines were increased in the PBC, consistent with the results of serum test. These findings indicated that saliva might be a less invasive and cost-effective medium to accurately test for AMA-M2 levels and this is a promising development for the diagnosis and monitoring of PBC.
28400582	0	9	Detection	T061	C1511790
28400582	13	19	AMA-M2	T116,T129	C0312621
28400582	23	28	human	T016	C0086418
28400582	29	35	saliva	T031	C0036087
28400582	37	47	Potentials	T080	C3245505
28400582	51	60	diagnosis	T033	C0011900
28400582	65	75	monitoring	T058	C1283169
28400582	79	106	primary biliary cholangitis	T047	C0008312
28400582	107	112	Serum	T031	C0229671
28400582	113	147	anti-mitochondrial antibody type 2	T116,T129	C0312621
28400582	149	155	AMA-M2	T116,T129	C0312621
28400582	184	193	biomarker	T201	C0005516
28400582	202	211	diagnosis	T033	C0011900
28400582	215	242	primary biliary cholangitis	T047	C0008312
28400582	244	247	PBC	T047	C0008312
28400582	259	276	serological tests	T059	C0036743
28400582	287	298	limitations	T169	C0449295
28400582	310	323	inconvenience	T033	C4062984
28400582	325	337	invasiveness	T080	C1301757
28400582	343	358	infection risks	T033	C0582147
28400582	368	372	less	T080	C0547044
28400582	373	381	invasive	T080	C0205281
28400582	382	390	approach	T082	C0449445
28400582	394	400	detect	T033	C0442726
28400582	401	413	AMA-M2 titer	T059	C1446191
28400582	440	448	salivary	T031	C0036087
28400582	449	455	AMA-M2	T116,T129	C0312621
28400582	459	468	potential	T080	C3245505
28400582	469	472	PBC	T047	C0008312
28400582	473	481	patients	T101	C0030705
28400582	497	503	AMA-M2	T116,T129	C0312621
28400582	513	521	detected	T033	C0442726
28400582	530	536	saliva	T031	C0036087
28400582	540	545	serum	T031	C0229671
28400582	546	561	AMA-M2-positive	T033	C4021051
28400582	562	565	PBC	T047	C0008312
28400582	566	574	patients	T101	C0030705
28400582	587	593	saliva	T031	C0036087
28400582	597	602	serum	T031	C0229671
28400582	603	618	AMA-M2-negative	T033	C0853205
28400582	619	622	PBC	T047	C0008312
28400582	623	631	patients	T101	C0030705
28400582	633	651	oral lichen planus	T047	C0206139
28400582	652	660	patients	T101	C0030705
28400582	662	665	OLP	T047	C0206139
28400582	667	675	patients	T101	C0030705
28400582	680	696	healthy controls	T080	C2986479
28400582	715	728	concentration	T081	C1446561
28400582	732	740	salivary	T031	C0036087
28400582	741	747	AMA-M2	T116,T129	C0312621
28400582	752	773	positively correlated	T080	C1707520
28400582	783	789	amount	T081	C1265611
28400582	793	798	serum	T031	C0229671
28400582	799	805	AMA-M2	T116,T129	C0312621
28400582	809	817	patients	T101	C0030705
28400582	823	831	salivary	T031	C0036087
28400582	832	854	inflammatory cytokines	T116,T129	C0079189
28400582	860	869	increased	T081	C0205217
28400582	877	880	PBC	T047	C0008312
28400582	882	897	consistent with	T078	C0332290
28400582	902	909	results	T169	C1274040
28400582	913	918	serum	T031	C0229671
28400582	919	923	test	T059	C0022885
28400582	955	961	saliva	T031	C0036087
28400582	973	977	less	T080	C0547044
28400582	978	986	invasive	T080	C0205281
28400582	991	1005	cost-effective	T057	C1511536
28400582	1006	1012	medium	T167	C1705217
28400582	1027	1031	test	T169	C0039593
28400582	1036	1049	AMA-M2 levels	T059	C2825862
28400582	1074	1085	development	T169	C1527148
28400582	1094	1103	diagnosis	T033	C0011900
28400582	1108	1118	monitoring	T058	C1283169
28400582	1122	1125	PBC	T047	C0008312